Sékouba Sidimé/LinkedIn
Jun 2, 2026, 19:42
Sékouba Sidimé: vWD vs Hemophilia A – The Classic USMLE Step 1 trap in Hematology
Sékouba Sidimé, Internal Medicine Physician, shared a post on LinkedIn:
“vWD vs Hemophilia A – The No. 1 USMLE Step 1 trap in Hematology
One lab result tells them apart.Here’s what you need to know:
von Willebrand Disease
- Prolonged aPTT, prolonged Bleeding time, decreased Ristocetin
- Female with a family history and mucocutaneous bleeding
- Treatment: Desmopressin (DDAVP)
Hemophilia A
- Prolonged aPTT , Bleeding time normal, Ristocetin normal
- Male with hemarthroses
- Treatment: Factor VIII replacement
The key:
vWF carries Factor VIII — decreased vWF results in secondary reduction of Factor VIII.
That’s why vWD affects both aPTT AND bleeding time.
Hemophilia A affects aPTT only.
If the examiner mentions Ristocetin then think vWD. Every time.”
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 01:37Lesley Van Wyk: Exploring Sickle Cell Disease – The HbS Story
-
Sep 15, 2026, 01:31Luca Seffin: To the Science, the People, and the Journey – Thank You SR-Tiget
-
Sep 14, 2026, 23:49Heghine Khachatryan: New evidance – Antiphospholipid Antibodies and Ischemic Stroke
-
Sep 14, 2026, 23:42Eman M. Elsabbagh: Successful HCT Does Not End at Engraftment
-
Sep 14, 2026, 23:31Antonis Kattamis: Proud to Be Part of this Endeavour and Senior Author of the Pivotal Trial
-
Sep 14, 2026, 23:23Farjah Algahtani: Stroke Incidence and Risk Factors in Saudi Patients with Sickle Cell Disease
-
Sep 14, 2026, 20:53YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value
-
Sep 14, 2026, 20:52Andres Alberto Mercado Pompa: External Validation of Prognostic Risk Scores in Cerebral Venous Thrombosis
-
Sep 14, 2026, 20:50Balaji Kirushnan: Advancing Regional Citrate Anticoagulation in CRRT – From Experience to Implementation